| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Yong-Xin Sun, Xunming Ji, Xiaoou Mao, Lin Xie, Jianping Jia, Veronica Galvan, David A Greenberg, Kunlin Ji. Differential activation of mTOR complex 1 signaling in human brain with mild to severe Alzheimer's disease. Journal of Alzheimer's disease : JAD. vol 38. issue 2. 2014-06-27. PMID:23979023. |
mammalian target of rapamycin (mtor) signaling has been suggested to be effective in modifying cognitive status in animal models of alzheimer's disease (ad), but little is known about its role in ad patients. |
2014-06-27 |
2023-08-12 |
human |
| Chun Yang, Bin Zhu, Jiang Shen, Tingting Hu, Zhangjun Li, Tao Hon. Rapamycin and mTOR inhibitors probably have therapeutic effects for post-operative cognitive dysfunction. Medical hypotheses. vol 81. issue 3. 2014-03-05. PMID:23850396. |
several lines of evidence have indicated that rapamycin acts as an inhibitor of mammalian target of rapamycin (mtor) and this produces therapeutic benefits as a treatment for alzheimer's disease (ad) by activating an autophagic pathway. |
2014-03-05 |
2023-08-12 |
Not clear |
| Yun-Qing Ma, Dong-Ke Wu, Jian-Kun Li. mTOR and tau phosphorylated proteins in the hippocampal tissue of rats with type 2 diabetes and Alzheimer's disease. Molecular medicine reports. vol 7. issue 2. 2013-11-04. PMID:23165862. |
mtor and tau phosphorylated proteins in the hippocampal tissue of rats with type 2 diabetes and alzheimer's disease. |
2013-11-04 |
2023-08-12 |
rat |
| Yun-Qing Ma, Dong-Ke Wu, Jian-Kun Li. mTOR and tau phosphorylated proteins in the hippocampal tissue of rats with type 2 diabetes and Alzheimer's disease. Molecular medicine reports. vol 7. issue 2. 2013-11-04. PMID:23165862. |
this study explored the effects of mammalian target of rapamycin (mtor) on the increased risk of developing alzheimer's disease (ad) in rats with type 2 diabetes mellitus (t2dm). |
2013-11-04 |
2023-08-12 |
rat |
| Yan Chen Shang, Zhao Zhong Chong, Shaohui Wang, Kenneth Maies. Wnt1 inducible signaling pathway protein 1 (WISP1) targets PRAS40 to govern β-amyloid apoptotic injury of microglia. Current neurovascular research. vol 9. issue 4. 2013-10-17. PMID:22873724. |
our work identifies wisp1, mtor signaling, and pras40 as targets for new strategies directed against alzheimer's disease and related disorders. |
2013-10-17 |
2023-08-12 |
Not clear |
| Antonella Caccamo, Andrea Magrì, David X Medina, Elena V Wisely, Manuel F López-Aranda, Alcino J Silva, Salvatore Odd. mTOR regulates tau phosphorylation and degradation: implications for Alzheimer's disease and other tauopathies. Aging cell. vol 12. issue 3. 2013-08-14. PMID:23425014. |
mtor regulates tau phosphorylation and degradation: implications for alzheimer's disease and other tauopathies. |
2013-08-14 |
2023-08-12 |
mouse |
| Zhi Tang, Erika Bereczki, Haiyan Zhang, Shan Wang, Chunxia Li, Xinying Ji, Rui M Branca, Janne Lehtiö, Zhizhong Guan, Peter Filipcik, Shaohua Xu, Bengt Winblad, Jin-Jing Pe. Mammalian target of rapamycin (mTor) mediates tau protein dyshomeostasis: implication for Alzheimer disease. The Journal of biological chemistry. vol 288. issue 22. 2013-08-06. PMID:23585566. |
mammalian target of rapamycin (mtor) mediates tau protein dyshomeostasis: implication for alzheimer disease. |
2013-08-06 |
2023-08-12 |
Not clear |
| Zhi Tang, Erika Bereczki, Haiyan Zhang, Shan Wang, Chunxia Li, Xinying Ji, Rui M Branca, Janne Lehtiö, Zhizhong Guan, Peter Filipcik, Shaohua Xu, Bengt Winblad, Jin-Jing Pe. Mammalian target of rapamycin (mTor) mediates tau protein dyshomeostasis: implication for Alzheimer disease. The Journal of biological chemistry. vol 288. issue 22. 2013-08-06. PMID:23585566. |
previous evidence from post-mortem alzheimer disease (ad) brains and drug (especially rapamycin)-oriented in vitro and in vivo models implicated an aberrant accumulation of the mammalian target of rapamycin (mtor) in tangle-bearing neurons in ad brains and its role in the formation of abnormally hyperphosphorylated tau. |
2013-08-06 |
2023-08-12 |
Not clear |
| Salvatore Odd. The role of mTOR signaling in Alzheimer disease. Frontiers in bioscience (Scholar edition). vol 4. 2013-08-05. PMID:22202101. |
the role of mtor signaling in alzheimer disease. |
2013-08-05 |
2023-08-12 |
Not clear |
| Zhao Zhong Chong, Yan Chen Shang, Shaohui Wang, Kenneth Maies. Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin. Progress in neurobiology. vol 99. issue 2. 2013-07-22. PMID:22980037. |
one novel therapeutic target that may offer promise for multiple disease entities that involve alzheimer's disease, parkinson's disease, epilepsy, trauma, stroke, and tumors of the nervous system is the mammalian target of rapamycin (mtor). |
2013-07-22 |
2023-08-12 |
Not clear |
| Kenneth Maiese, Zhao Zhong Chong, Yan Chen Shang, Shaohui Wan. mTOR: on target for novel therapeutic strategies in the nervous system. Trends in molecular medicine. vol 19. issue 1. 2013-06-11. PMID:23265840. |
recent studies highlight the importance of both traditional and newly recognized interactors of mtor, such as p70s6k, 4ebp1, gsk-3β, redd1/rtp801, tsc1/tsc2, growth factors, wingless, and forkhead transcription factors, that influence alzheimer's disease, parkinson's disease, huntington's disease, tuberous sclerosis, and epilepsy. |
2013-06-11 |
2023-08-12 |
Not clear |
| Gunnar K Goura. mTOR: at the crossroads of aging, chaperones, and Alzheimer's disease. Journal of neurochemistry. vol 124. issue 6. 2013-04-29. PMID:23278352. |
mtor: at the crossroads of aging, chaperones, and alzheimer's disease. |
2013-04-29 |
2023-08-12 |
Not clear |
| Andreas Müller-Schiffmann, Heinrich Sticht, Carsten Kort. Hybrid compounds: from simple combinations to nanomachines. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. vol 26. issue 1. 2012-05-07. PMID:22239618. |
examples are hybrid compounds against alzheimer's disease, against the cancer-relevant phosphoinisitide-3-kinase (pi3k)/akt/mammalian target of rapamycin (mtor) and epidermal growth factor signaling cascade, or in antimalarial therapy via simultaneous hitting of different mechanisms of hemozoin formation. |
2012-05-07 |
2023-08-12 |
Not clear |
| Giuseppe Pignataro, Domenico Capone, Giuliano Polichetti, Antonio Vinciguerra, Antonio Gentile, Gianfranco Di Renzo, Lucio Annunziat. Neuroprotective, immunosuppressant and antineoplastic properties of mTOR inhibitors: current and emerging therapeutic options. Current opinion in pharmacology. vol 11. issue 4. 2011-12-12. PMID:21646048. |
in fact, mtor is involved in the mechanism of pi3k/akt-induced upregulation of glutamate transporter 1, glt1, that is linked to several neuronal disorders such as stroke, alzheimer's disease, and amyotrophic lateral sclerosis. |
2011-12-12 |
2023-08-12 |
Not clear |
| Zhao Zhong Chong, Yan Chen Shang, Lijie Zhang, Shaohui Wang, Kenneth Maies. Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders. Oxidative medicine and cellular longevity. vol 3. issue 6. 2011-07-26. PMID:21307646. |
the signaling pathways of mtor also are believed to be a significant component in a number of neurological diseases, such as alzheimer's disease, parkinson's disease, and huntington's disease, tuberous sclerosis, neurofibromatosis, fragile x syndrome, epilepsy, traumatic brain injury, and ischemic stroke. |
2011-07-26 |
2023-08-12 |
Not clear |
| Patricia Spilman, Natalia Podlutskaya, Matthew J Hart, Jayanta Debnath, Olivia Gorostiza, Dale Bredesen, Arlan Richardson, Randy Strong, Veronica Galva. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease. PloS one. vol 5. issue 4. 2011-06-16. PMID:20376313. |
inhibition of mtor by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of alzheimer's disease. |
2011-06-16 |
2023-08-12 |
mouse |
| Antonella Caccamo, Monica A Maldonado, Smita Majumder, David X Medina, Walter Holbein, Andrea Magrí, Salvatore Odd. Naturally secreted amyloid-beta increases mammalian target of rapamycin (mTOR) activity via a PRAS40-mediated mechanism. The Journal of biological chemistry. vol 286. issue 11. 2011-05-16. PMID:21266573. |
alterations in protein homeostasis and mtor activity and signaling have been reported in several neurodegenerative disorders, including alzheimer disease (ad); however, the causes of such deregulations remain elusive. |
2011-05-16 |
2023-08-12 |
mouse |
| Michael G Garelick, Brian K Kenned. TOR on the brain. Experimental gerontology. vol 46. issue 2-3. 2011-04-29. PMID:20849946. |
we will focus on recent studies investigating mtor and alzheimer's disease, parkinson's disease, and polyglutamine expansion syndromes such as huntington's disease. |
2011-04-29 |
2023-08-12 |
mouse |
| Tao Ma, Charles A Hoeffer, Estibaliz Capetillo-Zarate, Fangmin Yu, Helen Wong, Michael T Lin, Davide Tampellini, Eric Klann, Robert D Blitzer, Gunnar K Goura. Dysregulation of the mTOR pathway mediates impairment of synaptic plasticity in a mouse model of Alzheimer's disease. PloS one. vol 5. issue 9. 2011-02-18. PMID:20862226. |
dysregulation of the mtor pathway mediates impairment of synaptic plasticity in a mouse model of alzheimer's disease. |
2011-02-18 |
2023-08-12 |
mouse |
| Tao Ma, Charles A Hoeffer, Estibaliz Capetillo-Zarate, Fangmin Yu, Helen Wong, Michael T Lin, Davide Tampellini, Eric Klann, Robert D Blitzer, Gunnar K Goura. Dysregulation of the mTOR pathway mediates impairment of synaptic plasticity in a mouse model of Alzheimer's disease. PloS one. vol 5. issue 9. 2011-02-18. PMID:20862226. |
we explored the relationship between the mtor pathway and β-amyloid (aβ)-induced synaptic dysfunction, which is considered to be critical in the pathogenesis of alzheimer's disease (ad). |
2011-02-18 |
2023-08-12 |
mouse |